We developed a new high-throughput infection assay which allowed us to simultaneously test dozens of sequence variants of ACE2 for their ability to allow viral particles coated with the spike proteins from the SARS-CoV-2 variants of concern to enter the cell. This evidence concerns the gene ACE2 and infection.